Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment with the PARP-inhibitor PJ34 causes enhanced doxorubicin-mediated cell death in HeLa cells

31 Jan 2012

Abstract excerpt

Adjuvant therapies can incorporate a number of different drugs to minimize the cardiotoxicity of cancer chemotherapy, decrease the development of drug resistance and increase the overall efficacy of the treatment regime. Topoisomerase IIα is a major target of many commonly used anticancer drugs, where cell death is brought about by an accumulation of double-strand DNA breaks. Poly (ADP-ribose) polymerase (PARP)-1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22293659
DOI: 10.1097/cad.0b013e328350900f

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment with the PARP-inhibitor PJ34 causes enhanced doxorubicin-mediated cell death in HeLa cellsPMID 22293659Read ↗

Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication ArrestSemantic proximity Read ↗

New insights into the activities and toxicities of the old anticancer drug doxorubicinSemantic proximity Read ↗

Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes.Semantic proximity Read ↗

Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermiaSemantic proximity Read ↗

Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and CisplatinSemantic proximity Read ↗

Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agentSemantic proximity Read ↗

Anthracyclines as Topoisomerase II Poisons: From Early Studies to New PerspectivesSemantic proximity Read ↗

Discovery of a Dual Tubulin and Poly(ADP-Ribose) Polymerase-1 Inhibitor by Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, and Biological EvaluationSemantic proximity Read ↗

Pharmacogenomic Identification of Targets for Adjuvant Therapy with the Topoisomerase Poison CamptothecinSemantic proximity Read ↗

A Novel Methionine-Based Signaling Mechanism Regulating the Expression of Thymidylate SynthaseSemantic proximity Read ↗

PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cellsSemantic proximity Read ↗

Stat1 confers sensitivity to radiation in cervical cancer cells by controlling Parp1 levels: a new perspective for Parp1 inhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.